Target Name: ANO1
NCBI ID: G55107
Review Report on ANO1 Target / Biomarker Content of Review Report on ANO1 Target / Biomarker
ANO1
Other Name(s): tumor-amplified and overexpressed sequence 2 | anoctamin 1, calcium activated chloride channel | collagen alpha-1(I) chain-like | ANO1_HUMAN | ANO1 variant 1 | ORAOV2 | Anoctamin-1 (isoform a) | Transmembrane protein 16A (eight membrane-spanning domains) | INDMS | Discovered on gastrointestinal stromal tumors protein 1 | TAOS2 | anoctamin 1 | Transmembrane protein 16A | transmembrane protein 16A (eight membrane-spanning domains) | Anoctamin-1 | discovered on gastrointestinal stromal tumors protein 1 | Oral cancer overexpressed 2 | calcium activated chloride channel | Tumor amplified and overexpressed sequence 2 | TMEM16A | Ca2+-activated Cl- channel | oral cancer overexpressed 2 | Anoctamin 1, transcript variant 1 | FLJ10261 | Oral cancer overexpressed protein 2 | DOG1 | Tumor-amplified and overexpressed sequence 2

ANO1: A Potential Drug Target Or Biomarker for Various Diseases

ANO1 (Tumor-Amplified and Overexpressed Sequence 2) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer. The ANO1 gene is located on chromosome 1p36 and encodes a protein known as ANO1, which is involved in a variety of cellular processes, including cell signaling, cell adhesion, and tissue repair.

Recent studies have identified ANO1 as being overexpressed or amplified in various types of cancer, including breast, ovarian, and colorectal cancers. Overexpression of ANO1 has been associated with increased cancer cell proliferation and survival, and may contribute to the development and progression of these diseases.

In addition to its potential as a drug target or biomarker, ANO1 has also been identified as a potential therapeutic target for a variety of other conditions. For example, ANO1 has been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Additionally, ANO1 has been linked to the development of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

Another potential application of ANO1 as a drug target is its role in the treatment of uveal cancer, a type of eye cancer. Studies have shown that ANO1 is often overexpressed in uveal cancer cells, and that inhibiting ANO1 expression may be an effective way to treat this type of cancer. One potential approach to inhibiting ANO1 expression in uveal cancer cells is through the use of small molecules or antibodies that specifically target ANO1.

In addition to its potential as a drug target or biomarker, ANO1 has also been identified as a potential biomarker for cancer. The ANO1 gene has been shown to be expressed in a variety of tissues and fluids, including cancer cells, blood cells, and urine. Additionally, ANO1 has been shown to be overexpressed in various types of cancer, including cancer samples from patients with uveal cancer. These findings suggest that ANO1 may be a useful biomarker for the diagnosis and monitoring of cancer.

Overall, ANO1 is a gene that has the potential to be a drug target or biomarker for a variety of diseases, including cancer. Further research is needed to fully understand the role of ANO1 in these conditions and to develop effective treatments.

Protein Name: Anoctamin 1

Functions: Calcium-activated chloride channel (CaCC) (PubMed:20056604, PubMed:22178883, PubMed:21984732, PubMed:22946059, PubMed:32487539). Plays a role in transepithelial anion transport and smooth muscle contraction. Required for the normal functioning of the interstitial cells of Cajal (ICCs) which generate electrical pacemaker activity in gastrointestinal smooth muscles. Acts as a major contributor to basal and stimulated chloride conductance in airway epithelial cells and plays an important role in tracheal cartilage development. Required for CFTR activation by enhancing endoplasmic reticulum Ca(2+) store release and is also required for CFTR membrane expression (PubMed:28963502). Required for basal and ATP-dependent mucus secretion in airways and intestine, probably by controlling exocytosis of mucus-filled granules by providing Ca(2+) to an apical signaling compartment (By similarity). Contributes to airway mucus expression induced by interleukins IL3 and IL8 and by the asthma-associated protein CLCA1 and is required for expression of mucin MUC5AC (PubMed:33026825). However, was shown in another study not to be required for MUC5AC expression (PubMed:31732694). Plays a role in the propagation of Ca(2+) waves in Kolliker's organ in the cochlea and contributes to the refinement of auditory brainstem circuitries prior to hearing onset (By similarity). In vomeronasal sensory neurons, modulates spontaneous firing patterns in the absence of stimuli as well as the firing pattern of pheromone-evoked activity (By similarity). Responsible for calcium-activated chloride channel activity in type I taste cells of the vallate papillae (By similarity). Acts as a heat sensor in nociceptive neurons (By similarity). In dorsal root ganglion neurons, plays a role in mediating non-histaminergic Mas-related G-protein coupled receptor (MRGPR)-dependent itching, acting as a downstream effector of MRGPRs (By similarity). In the developing brain, required for the Ca(2+)-dependent process extension of radial glial cells (By similarity)

The "ANO1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANO1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ANO10 | ANO2 | ANO3 | ANO4 | ANO5 | ANO6 | ANO7 | ANO7L1 | ANO8 | ANO9 | Anoctamin | ANOS1 | ANOS2P | ANP32A | ANP32A-IT1 | ANP32AP1 | ANP32B | ANP32C | ANP32D | ANP32E | ANPEP | ANTKMT | ANTXR1 | ANTXR2 | ANTXRL | ANTXRLP1 | ANXA1 | ANXA10 | ANXA11 | ANXA13 | ANXA2 | ANXA2P1 | ANXA2P2 | ANXA2P3 | ANXA2R | ANXA2R-AS1 | ANXA2R-OT1 | ANXA3 | ANXA4 | ANXA5 | ANXA6 | ANXA7 | ANXA8 | ANXA8L1 | ANXA8L2 | ANXA9 | AOAH | AOC1 | AOC2 | AOC3 | AOC4P | AOPEP | AOX1 | AOX2P | AP-1 Transcription Factor Complex | AP1AR | AP1B1 | AP1B1P1 | AP1G1 | AP1G2 | AP1M1 | AP1M2 | AP1S1 | AP1S2 | AP1S3 | AP2A1 | AP2A2 | AP2B1 | AP2M1 | AP2S1 | AP3B1 | AP3B2 | AP3D1 | AP3M1 | AP3M2 | AP3S1 | AP3S2 | AP4B1 | AP4B1-AS1 | AP4E1 | AP4M1 | AP4S1 | AP5B1 | AP5M1 | AP5S1 | AP5Z1 | APAF1 | APBA1 | APBA2 | APBA3 | APBB1 | APBB1IP | APBB2 | APBB3 | APC | APC2 | APCDD1 | APCDD1L | APCDD1L-DT | APCS